Tazeen Ahmad
BofA Securities, Research Division

Good morning. I'm Tazeen Ahmad. I'm one of the senior biotech analysts at the bank. It's my pleasure to have our next presenting company with us, Alnylam Pharmaceuticals. Sitting up here on stage with me is Jeff Poulton, who is, of course, Chief Financial Officer.

Jeff, welcome back to Las Vegas. Thanks for making the trip.

Jeffrey Poulton
CFO & Executive VP

No, I always make the trip to Vegas. I'm always here for this one. So I appreciate the invite.

Tazeen Ahmad
BofA Securities, Research Division

Yes. We have to continue the tradition. So maybe we can start off with a quick overview of the company in case anyone in the room isn't as familiar with Alnylam and its platform.

Jeffrey Poulton
CFO & Executive VP

Yes. I mean we're a 25-year-old company. It was founded based on Nobel Prize winning science. RNAi is really a new modality that we've developed. It was a long haul to figure out some of the delivery challenges with the technology. But over the last 6 or 7 years now, they figured that out, and we've had a steady stream of products launching into the market. We've built the commercial side of the business, which I know we're going to talk a lot about here in the fireside chat.

We've transitioned the company from being a loss-making company to now being a profitable company. And we've put out new 2030 goals earlier this year to kind of provide a picture of where we think we're taking the company over the